On March 12, 2026, the European Data Protection Board (EDPB) and the European Data Protection Supervisor (EDPS) issued a Joint Opinion on the proposed European Biotech Act I, supporting its aim to bolster the EU biotech sector while stressing the need for stricter data protection measures, particularly regarding health data. Key recommendations include clarifying the legal basis for processing personal data in clinical trials, defining roles of clinical trial actors, limiting data sharing to what is necessary, and establishing safeguards for data retention and further processing. The Act is currently under review, with final adoption expected in late 2026, but it remains uncertain how much influence the EDPB and EDPS recommendations will have on the final legislation.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://datamatters.sidley.com/2026/04/29/european-biotech-act-i-navigating-the-edpb-edps-vision-for-the-future-of-clinical-trials/
